Literature DB >> 2770191

[Diagnosis of disseminated intravascular coagulation: the value of soluble fibrin, D-dimers and fibrin(ogen) split products].

J U Wieding1, G Eisinger, H Köstering.   

Abstract

The validity of the fibrin(ogen) derivatives 'soluble fibrin, D-dimers and fibrin(ogen) degradation products' was compared with other parameters in early and sensitive diagnosing of disseminated intravascular coagulation (DIC). In a clinical study 900 patients' samples from separate, defined groups were examined, including course observations of intensive care patients (n = 38) and patients with acute pancreatitis. The fibrin(ogen) derivatives correlated very well with the degree of blood coagulation disturbances: in particular, D-dimers and soluble fibrin proved to be more sensitive in early diagnosis of DIC than other parameters. The SF-PS-turbidimetry demonstrated a good validity and practicality in the quantitative determination of soluble fibrin, but a suitable analyzer is essential. Determination of D-dimers is preferable to that of fibrin(ogen) degradation products (both in the latex-agglutination test) because of the better sensitivity and practicality; even more sensitive results were provided by the D-dimer-ELISA, which is, however, not practical in acute diagnostics. The decrease in protein C was at least equally sensitive as the antithrombin III-levels in indicating the consumption of the hemostatic potential. The decrease of thrombocyte counts and fibrinogen levels could first be detected in a later stage of DIC. In conclusion, D-dimers and soluble fibrin can improve the DIC diagnostics, making them more reliable; additionally, antithrombin III and possibly protein C deserve further consideration, although the fibrin(ogen) derivatives are apparently of greater importance.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2770191     DOI: 10.1007/BF01745348

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  19 in total

1.  Determination of soluble fibrin in plasma by a rapid and quantitative spectrophotometric assay.

Authors:  B Wiman; M Rånby
Journal:  Thromb Haemost       Date:  1986-04-30       Impact factor: 5.249

2.  Measurement of crosslinked fibrin derivatives in plasma and ascitic fluid with monoclonal antibodies against D dimer using EIA and latex test.

Authors:  R Hafter; R Schröck; R von Hugo; H Graeff
Journal:  Scand J Clin Lab Invest Suppl       Date:  1985

3.  Disseminated intravascular coagulation. Findings in 346 patients.

Authors:  J A Spero; J H Lewis; U Hasiba
Journal:  Thromb Haemost       Date:  1980-02-29       Impact factor: 5.249

4.  [Detection of a thrombotic tendency by means of coagulation tests (author's transl)].

Authors:  E von Kaulla; K N von Kaulla
Journal:  MMW Munch Med Wochenschr       Date:  1974-08-02

5.  Pathophysiology, clinical manifestations and therapy of consumption-coagulopathy ("Verbrauchskoagulopathie").

Authors:  H G Lasch; D L Heene; K Huth; W Sandritter
Journal:  Am J Cardiol       Date:  1967-09       Impact factor: 2.778

6.  [Estimation of soluble fibrin monomer complexes for evaluation of hypercoagulability during pregnancy and delivery (author's transl)].

Authors:  R Hafter; T Schneebauer; K Tafel; E Ernst; H Graeff
Journal:  Geburtshilfe Frauenheilkd       Date:  1975-07       Impact factor: 2.915

7.  [Significance of early laboratory diagnosis for obstetrical procedures in severe gestoses and the HELLP syndrome].

Authors:  W Rath; W Loos; W Kuhn; H Graeff
Journal:  Geburtshilfe Frauenheilkd       Date:  1988-03       Impact factor: 2.915

8.  Estimation of coagulation-fibrinolytic factors in DIC.

Authors:  H Hasegawa
Journal:  Bibl Haematol       Date:  1983

9.  Discrimination between fibrin and fibrinogen by a monoclonal antibody against a synthetic peptide.

Authors:  U Scheefers-Borchel; G Müller-Berghaus; P Fuhge; R Eberle; N Heimburger
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

10.  Measurement of fibrinopeptide A in human blood.

Authors:  H L Nossel; I Yudelman; R E Canfield; V P Butler; K Spanondis; G D Wilner; G D Qureshi
Journal:  J Clin Invest       Date:  1974-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.